The merry-go-round of approval, pricing and reimbursement of drugs against the Hepatitis C virus infection in Spain
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Campillo Artero, Carlos
- dc.contributor.author Garcia-Armesto, Sandra
- dc.contributor.author Bernal Delgado, Enrique
- dc.date.accessioned 2023-06-06T06:27:12Z
- dc.date.available 2023-06-06T06:27:12Z
- dc.date.issued 2016
- dc.description.abstract Given that drug innovation has been largely away from breakthroughs, arguing that a new drug recently approved and reaching the market is downright effective, safe and affordable is actually parlous. The soaring costs of an increasing number of new drugs (specially for cancer and rare diseases) threaten to supersede societal absorbing capacity, competing with other health and outside health sector resources. Some health systems are not making headways towards solving the current conundrum of keeping path with the state of the art regulatory mechanisms in delivering cost-effective, equitable and affordable treatments. The way pricing and reimbursement decisions have been made in Spain regarding the recent wave of new drugs against the hepatitis C virus could be one case in point. This paper analyses the path of decision-making and the positioning of the relevant actors in this case, that has set a cumbersome precedent (earmarked fund) for the Spanish National Health Service. It also stresses the need for current decision-making mechanisms on approval, pricing, coverage and reimbursement in Spain to move to a transparent regulatory system, avoiding improvisation and incorporating the highest regulatory standards that other countries have in place.
- dc.format.mimetype application/pdf
- dc.identifier.citation Campillo-Artero C, Garcia-Armesto S, Bernal-Delgado E. The merry-go-round of approval, pricing and reimbursement of drugs against the Hepatitis C virus infection in Spain. Health Policy. 2016 Sep;120(9):975-81. DOI: 10.1016/j.healthpol.2016.07.005
- dc.identifier.doi http://dx.doi.org/10.1016/j.healthpol.2016.07.005
- dc.identifier.issn 0168-8510
- dc.identifier.uri http://hdl.handle.net/10230/57076
- dc.language.iso eng
- dc.publisher Elsevier
- dc.relation.ispartof Health Policy. 2016 Sep;120(9):975-81
- dc.rights © 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
- dc.subject.keyword Pharmaceuticals’ pricing
- dc.subject.keyword Coverage
- dc.subject.keyword Reimbursement
- dc.subject.keyword Hepatitis C drugs
- dc.subject.keyword High-price pharmaceuticals
- dc.subject.keyword Value-based pricing
- dc.subject.keyword Budgetary silos
- dc.title The merry-go-round of approval, pricing and reimbursement of drugs against the Hepatitis C virus infection in Spain
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion